Literature DB >> 12420610

Palliative treatment in "peri"-pancreatic carcinoma: stenting or surgical therapy?

N T van Heek1, R C I van Geenen, O R C Busch, D J Gouma.   

Abstract

Mostly, patients with peri-pancreatic cancer (including pancreatic, ampullary and distal bile duct tumors) are diagnosed in a stage in which curative resection is not possible. The median survival rate of patients with non resectable peri-pancreatic cancer varies between 6 and 12 months. During this period palliative treatment is necessary, which should focus on major symptoms as obstructive jaundice, duodenal obstruction and pain. Controversy exists about how to provide optimal palliative treatment. Both surgical and non surgical palliative procedures relief obstructive jaundice. From early retrospective and prospective randomized studies it is known that in the early phase after treatment, more complications are found after surgical palliation, whereas in the late phase more complications are seen after endoscopic palliation. Because more recent studies clearly showed improved results after surgical palliation, current recommendations probably should be that patients with a suspected poor short-term survival (< 6 months) should be offered non surgical palliative therapy and those with a longer life expectancy may best be treated with bypass surgery. Unfortunately, valid criteria for estimating the remaining survival time are not available, except for the presence of metastases. The use of a prognostic score chart might assist in estimating the prognosis. Literature does not give sufficient information to make a well deliberated (evidence based) selection between the different types of surgical bypasses, but a choledochojejunostomy is generally preferred. After stenting, a correlation is found between survival and the development of duodenal obstruction, and between 9% and 21% of the patients who underwent a surgical biliary bypass without a prophylactic gastric bypass, will develop gastric outlet obstruction. Therefore, in patients with a relatively good prognosis it is recommended to perform routinely a double--biliary and gastric--bypass. Pain is a frequent symptom and is related with poor survival. Pain management aside from pain medication can be performed by means of a celiac plexus blockade or a thorascopic splanchnicectomy, and also radiotherapy seems to have a positive result on pain.

Entities:  

Mesh:

Year:  2002        PMID: 12420610

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  20 in total

Review 1.  Role of stenting in gastrointestinal benign and malignant diseases.

Authors:  Benedetto Mangiavillano; Nico Pagano; Monica Arena; Stefania Miraglia; Pierluigi Consolo; Giuseppe Iabichino; Clara Virgilio; Carmelo Luigiano
Journal:  World J Gastrointest Endosc       Date:  2015-05-16

2.  Enteral stenting versus gastrojejunostomy for palliation of malignant gastric outlet obstruction.

Authors:  Mouen Khashab; Ahmad S Alawad; Eun Ji Shin; Katherine Kim; Nicolas Bourdel; Vikesh K Singh; Anne Marie Lennon; Susan Hutfless; Reem Z Sharaiha; Stuart Amateau; Patrick I Okolo; Martin A Makary; Christopher Wolfgang; Marcia Irene Canto; Anthony N Kalloo
Journal:  Surg Endosc       Date:  2013-01-09       Impact factor: 4.584

3.  Stomach-interposed cholecystogastrojejunostomy: a palliative approach for periampullary carcinoma.

Authors:  Chun-Yi Hao; Xiang-Qian Su; Jia-Fu Ji; Xin-Fu Huang; Bao-Cai Xing
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

Review 4.  Advanced-stage pancreatic cancer: therapy options.

Authors:  Jens Werner; Stephanie E Combs; Christoph Springfeld; Werner Hartwig; Thilo Hackert; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2013-04-30       Impact factor: 66.675

5.  EUS-guided gastroenterostomy is comparable to enteral stenting with fewer re-interventions in malignant gastric outlet obstruction.

Authors:  Yen-I Chen; Takao Itoi; Todd H Baron; Jose Nieto; Yamile Haito-Chavez; Ian S Grimm; Amr Ismail; Saowanee Ngamruengphong; Majidah Bukhari; Gulara Hajiyeva; Ahmad S Alawad; Vivek Kumbhari; Mouen A Khashab
Journal:  Surg Endosc       Date:  2016-11-10       Impact factor: 4.584

Review 6.  Treatment of malignant gastric outlet obstruction with endoscopically placed self-expandable metal stents.

Authors:  Jill K J Gaidos; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

7.  The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life.

Authors:  N Tjarda Van Heek; Steve M M De Castro; Casper H van Eijck; Rutger C I van Geenen; Eric J Hesselink; Paul J Breslau; T C Khe Tran; Geert Kazemier; Mechteld R M Visser; Olivier R C Busch; Hugo Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

Review 8.  Nutritional Support of Cancer Patients without Oral Feeding: How to Select the Most Effective Technique?

Authors:  Gonçalo Nunes; Jorge Fonseca; Ana Teresa Barata; Mário Dinis-Ribeiro; Pedro Pimentel-Nunes
Journal:  GE Port J Gastroenterol       Date:  2019-10-07

9.  Surgical bypass versus endoscopic stenting for malignant gastroduodenal obstruction: a decision analysis.

Authors:  Ali Siddiqui; Stuart J Spechler; Sergio Huerta
Journal:  Dig Dis Sci       Date:  2006-12-08       Impact factor: 3.487

10.  [Palliative endoscopy].

Authors:  Benno Arnstadt; Hans-Dieter Allescher
Journal:  Chirurg       Date:  2021-06-17       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.